Search

Displaying results 6161 - 6170 of 8006 in total
  1. Drug

    TTX-MC138

    go.drugbank.com/drugs/DB18628
    Investigational

    [L48335] It is under investigation for the treatment of various metastatic cancers.

  2. Drug

    Rilvegostomig

    go.drugbank.com/drugs/DB18991
    Investigational

    Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).

  3. Drug

    Lefitolimod

    go.drugbank.com/drugs/DB15061
    Investigational

    Lefitolimod is under investigation in clinical trial NCT03837756 (Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV).

  4. Drug

    FET F-18

    go.drugbank.com/drugs/DB15405
    Investigational

    FET F-18 is under investigation in clinical trial NCT01756352 (FET-PET for Evaluation of Response of Recurrent GBM to Avastin).

  5. Drug

    Imidocarb

    go.drugbank.com/drugs/DB11521
    ExperimentalVet approved

    Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.

  6. Drug

    Etiracetam

    go.drugbank.com/drugs/DB11868
    Experimental

    Etiracetam is under investigation in clinical trial NCT01137110 (Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)).

  7. Drug

    Ribaxamase

    go.drugbank.com/drugs/DB16311
    Investigational

    Ribaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).

  8. Drug

    OTX-2002

    go.drugbank.com/drugs/DB17246
    Investigational

    OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).

  9. Drug

    BNT111

    go.drugbank.com/drugs/DB18177
    Investigational

    BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.

  10. Drug

    GW-468816

    go.drugbank.com/drugs/DB15099
    Experimental

    GW-468816 is under investigation in clinical trial NCT00218465 (Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking).